文献速递细菌感染、耐药与抗菌药物医院感染防控

鼻拭子PCR指导ICU疑似社区获得性肺炎经验性万古霉素降阶梯的随机对照试验

Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin: A Randomized Controlled Trial.
PubMed 文献 · Clin Infect Dis · 2026-01-01

STOP-Vanc为单中心前瞻性非盲随机试验,纳入277例疑似社区获得性肺炎的成人ICU患者,1:1随机接受常规治疗加或不加MRSA鼻拭子PCR检测。

要点

  • MRSA鼻拭子PCR在危重患者中阴性预测值高达98.9%。
  • PCR检测未显著缩短万古霉素使用时间或降低30天死亡率。
  • 可能需要结合临床医生教育与抗菌药物管理干预才能减少万古霉素使用。

核心结论

  • 尽管MRSA鼻拭子PCR在危重患者中显示高阴性预测值,但未能减少ICU疑似CAP患者的万古霉素使用时间或30天死亡率。

研究设计与样本

  • STOP-Vanc为实用型、前瞻性、单中心、非盲随机对照试验,纳入277例疑似社区获得性肺炎的成人ICU患者,1:1随机分为干预组(加MRSA鼻拭子PCR检测)和对照组(常规治疗)。

主要发现

  • 干预组MRSA PCR鼻拭子检测的阴性预测值为98.9%。
  • MRSA PCR鼻拭子检测未降低30天死亡率。

临床怎么用

  • 在ICU疑似CAP患者中,不应仅依赖MRSA鼻拭子PCR检测来缩短经验性万古霉素疗程。
  • 需结合临床医生教育和抗菌药物管理干预来减少该人群的万古霉素使用。

局限性

  • 单中心、非盲设计可能影响结果外推。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fear of methicillin-resistant Staphylococcus aureus (MRSA) as a cause of community-acquired pneumonia (CAP) frequently leads to empiric vancomycin coverage. Data evaluating the use of MRSA polymerase chain reaction (PCR) nasal swab testing to guide vancomycin de-escalation is limited for patients in the intensive care unit (ICU). METHODS: Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin (STOP-Vanc) is a pragmatic, prospective, single-center, non-blinded randomized trial in which adult ICU patients with suspicion of CAP were randomized 1:1 to receive usual care either with (intervention) or without (control) the addition of MRSA nares PCR testing following ICU admission. The primary outcome was vancomycin-free hours alive, defined as the expected number of hours alive and free of vancomycin use within the first 7 days of trial enrollment as estimated using a longitudinal proportional odds state transition model adjusted for baseline covariates. RESULTS: A total of 277 adult ICU patients were randomized. Methicillin-resistant Staphylococcus aureus PCR nasal swab testing had a negative predictive value (NPV) of 98.9% in the intervention arm. The primary endpoint, vancomycin-free hours alive, was 105.7 in the control arm and 109.7 in the intervention arm (adjusted difference, 4 hours; 95% CI, -9.5-18.2; P = .458). CONCLUSIONS: Despite MRSA PCR nasal swab testing demonstrating a high NPV in this critically ill population, MRSA PCR nasal swab testing did not decrease the duration of vancomycin use or 30-day mortality among ICU patients with suspected CAP. Additional clinician education and antimicrobial stewardship interventions might be needed to reduce vancomycin use in this patient population. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov NCT06272994 (STOP-Vanc).

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Freiberg JA, Qian ET, Nairon KG, et al. Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin: A Randomized Controlled Trial. Clin Infect Dis. 2026. PMID: 42227019. doi:10.1093/cid/ciag295

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。